Natural Bioactive Compounds from Fungi as Potential Candidates for Protease Inhibitors and Immunomodulators to Apply for Coronaviruses

• Published in: Molecules (Basel, Switzerland) Vol. 25; no. 8; p. 1800
• Main Authors: Suwannarach, Nakarin, Kumla, Jaturong, Sujarit, Kanaporn, Pattananandecha, Thanawat, Saenjum, Chalermpong, Lumyong, Saisamorn
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 14.04.2020; MDPI
• Subjects: antiviral agents; Antiviral Agents - chemistry; Antiviral Agents - pharmacology; Antiviral drugs; Biological Products - chemistry; Biological Products - isolation & purification; Biological Products - pharmacology; Coronavirus - drug effects; Coronavirus - enzymology; Coronavirus Infections - drug therapy; Coronavirus Infections - virology; Coronaviruses; COVID-19; Disease transmission; drug discovery; Drugs; Epidemics; FDA approval; fungal metabolites; Fungi; Fungi - chemistry; HIV; Human immunodeficiency virus; Humans; Immunologic Factors - chemistry; Immunologic Factors - isolation & purification; Immunologic Factors - pharmacology; immunomodulatory agents; Infections; Middle East respiratory syndrome; Molecular Structure; Molecular weight; Mortality; natural products; Peptides; Pneumonia; Prevention; Protease Inhibitors - chemistry; Protease Inhibitors - isolation & purification; Protease Inhibitors - pharmacology; Proteins; Respiratory diseases; Review; RNA polymerase; Severe acute respiratory syndrome coronavirus 2; Structure-Activity Relationship; Viral infections; Viruses; China; natural products; coronaviruses; drug discovery; fungal metabolites; immunomodulatory agents; antiviral agents

The inhibition of viral protease is an important target in antiviral drug discovery and development. To date, protease inhibitor drugs, especially HIV-1 protease inhibitors, have been available for human clinical use in the treatment of coronaviruses. However, these drugs can have adverse side effec...